Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 461

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 461
---
 | ​ | ​ | ​ | ​    | ​ |  6,900,000 | ​ | ​ |
| Basic and diluted net (loss) income per share, Class B common stock                                        | ​ | ​ | ​                                | $ |      -0.15 | ​ | ​ | ​ | ​    | $ |       0.30 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-30

TABLE OF CONTENTS IRIS ACQUISITION CORP
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

| ​                                                             
 ​                                                             | ​ 
 ​ | ​ 
 ​ | Class ACommon Stock 
 Shares              |   |           |   | ​ | ​ | Amount |   |     |   | ​ 
 ​ | ​ 
 ​ | Class BCommon Stock 
 Shares              |   |            |   | ​ | ​ | Amount |   |      |   | ​ 
 ​ | ​ | AdditionalPaid-inCapital |   |         |   | ​ | ​ | AccumulatedDeficit |   |             |   | ​ | ​ | TotalStockholders’Deficit |   |             |   | ​ |
|:--------------------------------------------------------------|:--|:--|:--------------------|:--|----------:|:--|:--|:--|:-------|:--|----:|:--|:--|:--|:--------------------|:--|-----------:|:--|:--|:--|:-------|:--|-----:|:--|:--|:--|:-------------------------|:--|--------:|:--|:--|:--|:-------------------|:--|------------:|:--|:--|:--|:--------------------------|:--|------------:|:--|:--|
| Balance – January 1, 2022                                     | ​ | ​ | ​                   | ​ |         — | ​ | ​ | ​ | ​      | $ |   — | ​ | ​ | ​ | ​                   | ​ |  6,900,000 | ​ | ​ | ​ | ​      | $ |  690 | ​ | ​ | ​ | ​                        | $ |       — | ​ | ​ | ​ | ​                  | $ | -21,131,825 | ​